Početna › B-stanični limfom › Pennsylvania
Kliničke studije za B-stanični limfom u državi Pennsylvania
16 studija za B-stanični limfom traži sudionike na lokacijama u državi Pennsylvania.
Gradovi u državi Pennsylvania
Službeni tekst studije (engleski)
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Philadelphia, Philadelphia
U tijeku regrutacijaOpažajna studija
Od 0 do 38 godina · Oba spola · Ažurirano 1. lis 2026. · NCT06131801A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Penn State Milton S Hershey Medical Center, Hershey
- McGlinn Cancer Institute, West Reading
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT06742996A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Pennsylvania Abramson Cancer Center, Philadelphia
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07101328A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Children's Hospital of Philadelphia, Philadelphia
U tijeku regrutacijaFaza 1
Od 0 do 18 godina · Oba spola · Ažurirano 16. ruj 2026. · NCT06173518Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Philadelphia
- Research Site, Pittsburgh
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 11. ruj 2026. · NCT06526793A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Fox Chase Cancer Center, Philadelphia
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 11. ruj 2026. · NCT06634589A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Philadelphia
- Research Site, Pittsburgh
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT06564038Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- UPMC Hillman Cancer Center, Pittsburgh
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT07520006Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Lehigh Valley Topper Cancer Center Institute, Allentown
- Thomas Jefferson University, Philadelphia
- West Penn Hospital, Pittsburgh
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT05826535A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT04104776CD45BE-HSPC + CART-45 Cells
- University of Pennsylvania, Philadelphia
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 10. kol 2026. · NCT07451054A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Allegheny Health Network, Pittsburgh
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 4. kol 2026. · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Allegheny Health Network Cancer Institute, Pittsburgh
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 13. srp 2026. · NCT04792489SynKIR-310 for Relapsed/Refractory B-NHL
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 14. tra 2026. · NCT06544265Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
- AHN Cancer Institute - West Penn Hospital, Pittsburgh
U tijeku regrutacijaFaza 2
Od 18 do 79 godina · Oba spola · Ažurirano 13. sij 2025. · NCT05281809Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital of Philadelphia, Philadelphia
U tijeku regrutacijaFaza 1
Od 1 do 21 godina · Oba spola · Ažurirano 6. pro 2024. · NCT05476770Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.